In poor metabolizers of CYP2D6, Brexpiprazole dose should be reduced by what percentage?

Unlock all questions

This demo includes only 20 questions. Upgrade to access hundreds of questions, flashcards, exam simulations, and disable ads.

Full question bankExam simulationsFlashcards
From $24.99Unlock all

Master HIV/AIDS Antiretroviral Therapy Test with comprehensive flashcards and multiple-choice questions. Each question provides detailed explanations to enhance your knowledge. Prepare effectively and excel in your exam!

Multiple Choice

In poor metabolizers of CYP2D6, Brexpiprazole dose should be reduced by what percentage?

Explanation:
In pharmacogenomics, how a drug is cleared depends on the activity of enzymes like CYP2D6. Brexpiprazole is mainly metabolized by CYP2D6, so people who are poor metabolizers have reduced enzyme activity. This leads to higher drug levels and longer exposure if the standard dose is used. To achieve similar systemic exposure as normal (extensive) metabolizers, the dose needs to be reduced by about half. This helps maintain efficacy while reducing the risk of adverse effects from too-high drug levels. Smaller reductions wouldn’t offset the increased exposure, while larger reductions could under-treat.

In pharmacogenomics, how a drug is cleared depends on the activity of enzymes like CYP2D6. Brexpiprazole is mainly metabolized by CYP2D6, so people who are poor metabolizers have reduced enzyme activity. This leads to higher drug levels and longer exposure if the standard dose is used. To achieve similar systemic exposure as normal (extensive) metabolizers, the dose needs to be reduced by about half. This helps maintain efficacy while reducing the risk of adverse effects from too-high drug levels. Smaller reductions wouldn’t offset the increased exposure, while larger reductions could under-treat.

More Multiple Choice Questions
Subscribe

Get the latest from Examzify

You can unsubscribe at any time. Read our privacy policy